Advertisement

Medicinal Chemistry Research

, Volume 27, Issue 9, pp 2071–2078 | Cite as

Synthesis of NSAIDs–Se derivatives as potent anticancer agents

  • lei Liu
  • Shaolei Li
  • Xiaolong Li
  • Min Zhong
  • Yin Lu
  • Yang Jiajie
  • Zhang Yongmin
  • Xianran He
Original Research
  • 127 Downloads

Abstract

In the present study, a series of NSAIDs–Se derivatives include selenocyanates and diselenides were synthesized and characterized, their anticancer activities against the human cancer cell lines SW480, HeLa, A549, and HepG2 were determined. Interestingly, most of the new compounds showed active in reducing the viability of different cancer lines. Compounds 1a and 1m exhibited higher promising activities than other derivatives. As the most active compound 1a showed IC50 values lower than 20 μM against the four cancer cell lines, particularly against SW480 with IC50 values below 10 μm, it shows the potential to be a promising molecular chemotherapeutic agent for colorectal cancer.

Keywords

Selenocyanates Diselenides NSAIDs Anticaner 

Notes

Acknowledgements

This investigation was made possible through the financial support of National Natural Science Foundation of China (Grant No: 21302065).

Compliance with ethical standards

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that caninappropriately influence our work, there is no professional or other personal interest of any nature or kind inany product, service and/or company that could be construed as influencing the position presented in, or thereview of, the manuscript entitled “Synthesis of NSAIDs–Se derivatives as potent anticancer agents”.

Supplementary material

44_2018_2216_MOESM1_ESM.doc (3 mb)
Supplementary Information

References

  1. Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62:444–449CrossRefPubMedGoogle Scholar
  2. Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD (2012) Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord 12:93CrossRefPubMedPubMedCentralGoogle Scholar
  3. Arafa SA, Abdelazeem AH, Arab HH, Omar HA (2014) OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro. Acta Pharmacol Sin 35:394–400CrossRefPubMedCentralGoogle Scholar
  4. Baines A, Taylor-Parker M, Goulet AC, Renaud C, Gerner EW, Nelson MA (2002) Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 1:370–374CrossRefPubMedGoogle Scholar
  5. Bodnar M, Konieczka P, Namiesnik J (2012) The properties, functions, and use of selenium compounds in living organisms. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 30:225–252CrossRefGoogle Scholar
  6. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS (2007) Long-term aspirin use and mortality in women. Arch Intern Med 167:562–572CrossRefPubMedGoogle Scholar
  7. Desai D, Sinha I, Null K, Wolter W, Suckow MA, King T, Amin S, Sinha R (2010) Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells. Int J Cancer 127:230–238CrossRefPubMedGoogle Scholar
  8. Fernandes AP, Gandin V (2015) Selenium compounds as therapeutic agents in cancer. Biochim Biophys Acta 1850:1642–1660CrossRefPubMedGoogle Scholar
  9. Ghose A, Fleming J, El-Bayoumy K, Harrison PR (2001) Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res 61:7479–7487PubMedGoogle Scholar
  10. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sorensen HT (2012) Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 118:4768–4776CrossRefPubMedGoogle Scholar
  11. Kontogiorgis CA, Hadjipavlou-Litina DJ (2002) Non steroidal anti-inflammatory and anti-allergy agents. Curr Med Chem 9:89–98CrossRefPubMedGoogle Scholar
  12. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC (2006) Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66:1070–1075CrossRefPubMedGoogle Scholar
  13. Omar HA, Arafa SA, Maghrabi IA, Weng JR (2014) Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor. Basic Clin Pharmacol Toxicol 114:464–471CrossRefPubMedGoogle Scholar
  14. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K (2007) Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 120:1410–1417CrossRefPubMedGoogle Scholar
  15. Plano D, Baquedano Y, Moreno-Mateos D, Font M, Jimenez-Ruiz A, Palop JA, Sanmartin C (2011) Selenocyanates and diselenides: a new class of potent antileishmanial agents. Eur J Med Chem 46:3315–3323CrossRefPubMedGoogle Scholar
  16. Plano D, Karelia DN, Pandey MK, Spallholz JE, Amin S, Sharma AK (2016) Design, synthesis, and biological evaluation of novel selenium (Se-NSAID) molecules as anticancer agents. J Med Chem 59:1946–1959CrossRefPubMedGoogle Scholar
  17. Poerschke RL, Franklin MR, Moos PJ (2008) Modulation of redox status in human lung cell lines by organoselenocompounds: selenazolidines, selenomethionine, and methylseleninic acid. Toxicol In Vitro 22:1761–1767CrossRefPubMedPubMedCentralGoogle Scholar
  18. Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612CrossRefPubMedGoogle Scholar
  19. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 376:1741–1750CrossRefPubMedGoogle Scholar
  20. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK (2012) Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 172:209–216CrossRefPubMedGoogle Scholar
  21. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S (2008) Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem 51:7820–7826CrossRefPubMedPubMedCentralGoogle Scholar
  22. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM (2000) 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 92:1136–1142CrossRefPubMedGoogle Scholar
  23. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • lei Liu
    • 1
  • Shaolei Li
    • 2
  • Xiaolong Li
    • 2
  • Min Zhong
    • 3
    • 4
  • Yin Lu
    • 4
  • Yang Jiajie
    • 4
  • Zhang Yongmin
    • 1
    • 5
  • Xianran He
    • 1
    • 3
  1. 1.Institute for Interdisciplinary ResearchJianghan UniversityWuhanPeople’s Republic of China
  2. 2.Shenzhen Fushan Biological Technology Co., LtdShenzhenPeople’s Republic of China
  3. 3.Key Laboratory of Optoelectronic Chemical Materials and Devices, Ministry of Education, School of Chemical and Environmental EngineeringJianghan UniversityWuhanPeople’s Republic of China
  4. 4.School of Chemical and Environmental EngineeringJianghan UniversityWuhanPeople’s Republic of China
  5. 5.Institut Parisien de Chimie Moléculaire, CNRS UMR 7201Université Pierre et Marie Curie-Paris 6ParisFrance

Personalised recommendations